secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-08-17T21:28:26+00:00
Accession:  0001104659-26-097951
Event type: dividend
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus declares special CVR dividend for legacy biosimilar asset proceeds
--------------------------------------------------------------------------

- One CVR per share of common stock; record date Sept 30, 2026, distribution Oct 7, 2026.
- CVRs entitle holders to net cash proceeds from sale/licensing of Legacy BioSim Assets (patents, IP, royalties, cell lines).
- CVRs non-transferable, no trading market, expire Oct 7, 2028; no guaranteed payment.
- Company retained investment bank as capital markets advisor for sale process; Loan Agreement with Innovatus Life Sciences restricts dispositions.
- CVRs not certificated, no voting rights, no interest; tax treatment uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/0001104659-26-097951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/chrs-20260817x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-097951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer